Trials / Completed
CompletedNCT03665285
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- NextCure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
Conditions
- Advanced or Metastatic Solid Tumors
- Lung Cancer
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Endometrial Cancer
- Melanoma
- CRC
- Urothelial Carcinoma
- Cholangiocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NC318 | NC318 is an experimental antibody drug that may make the immune response more active against cancer. |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2023-04-11
- Completion
- 2023-04-11
- First posted
- 2018-09-11
- Last updated
- 2024-03-08
- Results posted
- 2024-03-08
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03665285. Inclusion in this directory is not an endorsement.